• Maria José Sá, Carlos Basílio, Carlos Capela, José João Cerqueira, Irene Mendes, Armando Morganho, João Correia de Sá, Vasco Salgado, Martins SilvaAnaAServiço de Neurologia. Centro Hospitalar Universitário do Porto. Porto. Portugal., José Vale, and Lívia Sousa.
• Serviço de Neurologia. Centro Hospitalar e Universitário de São João. Porto. Portugal.
• Acta Medica Port. 2023 Mar 1; 36 (3): 167173167-173.

IntroductionMultiple sclerosis is a disease with a heterogeneous evolution. The early identification of secondary progressive multiple sclerosis is a clinical challenge, which would benefit from the definition of biomarkers and diagnostic tools applicable in the transition phase from relapsing-remitting multiple sclerosis to secondary progressive multiple sclerosis. We aimed to reach a Portuguese national consensus on the monitoring of patients with multiple sclerosis and on the more relevant clinical variables for the early identification of its progression.Material And MethodsA Delphi panel which included eleven Portuguese Neurologists participated in two rounds of questions between July and August of 2021. In the first round, 39 questions which belonged to the functional, cognitive, imaging, biomarkers and additional evaluations were included. Questions for which no consensus was obtained in the first round (less than 80% of agreement), were appraised by the panel during the second round.ResultsThe response rate was 100% in both rounds and consensus was reached for a total of 33 questions (84.6%). Consensus was reached for monitoring time, evaluation scales and clinical variables such as the degree of brain atrophy and mobility reduction, changes suggestive of secondary progressive multiple sclerosis. Additionally, digital devices were considered tools with potential to identify disease progression. Most questions for which no consensus was obtained referred to the cognitive assessment and the remaining referred to both functional and imaging domains.ConclusionConsensus was obtained for the determination of the monitorization interval and for most of the clinical variables. Most questions that did not reach consensus were related with the confirmation of progression taking into account only one test/domain, reinforcing the multifactorial nature of multiple sclerosis.

9 keywords...

hide…